Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689681 | 1.00 | EBP (0.39) | EBPSIGMAR1DHCR7NOTUMLMNA | |
| SCHEMBL1689761 | 0.91 | DRD2 (0.43) | EBPSIGMAR1DHCR7LMNADRD2 | |
| SCHEMBL1689759 | 0.91 | DRD2 (0.43) | EBPSIGMAR1DHCR7LMNADRD2 | |
| SCHEMBL1689647 | 0.82 | NOTUM (0.64) | EBPSIGMAR1DHCR7NOTUMLMNA | |
| SCHEMBL1689652 | 0.82 | NOTUM (0.64) | EBPSIGMAR1DHCR7NOTUMLMNA | |
| SCHEMBL10253686 | 0.80 | AKT1 (0.34) | EBPSIGMAR1DHCR7NOTUMLMNA | |
| SCHEMBL14303463 | 0.79 | DRD2 (0.46) | EBPSIGMAR1DHCR7LMNADRD2 | |
| SCHEMBL4129887 | 0.79 | NPY5R (0.38) | DHCR7NOTUMPTGDR2MEN1KMT2A | |
| SCHEMBL4129892 | 0.79 | NPY5R (0.38) | DHCR7NOTUMPTGDR2MEN1KMT2A | |
| SCHEMBL1689843 | 0.79 | NOTUM (0.39) | EBPSIGMAR1DHCR7NOTUMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | EBP 1155/4885SIGMAR1 85/4885DHCR7 2473/4885 |
| US-20060106045-A1 | Spiroindolinepiperidine derivatives | RECQL, OPRD1, NCAPD3 | EBP 987/4885SIGMAR1 143/4885DHCR7 2616/4885 |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | EBP 1155/4885SIGMAR1 85/4885DHCR7 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.